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Objective:  The  purpose  of  the  study  was  to  assess  the  efﬁcacy  and safety  of using  Chinese  herbal  medicine
(CHM)  as  maintenance  therapy  considering  the  survival  of  advanced  non-small-cell  lung  cancer  (NSCLC)
patients after  ﬁrst-line  conventional  platinum-based  chemotherapy.
Design:  An open-label,  randomized,  controlled  trial.
Setting:  Four  hospitals  in  China.
Interventions  and  main  outcome  measures:  A total  of 106  patients  were  eligible  and  randomly  divided  into
two  groups  from  four  hospitals  in  China.  Both  groups  received  the  best  supporting  care  (BSC).  Additionally,
patients  in the trial group  were  given  CHM  every  day  until  the  disease  became  aggravated  or  the  patients
resigned.  The  study  took  both  progression-free  survival  (PFS)  and  quality  of life (QOL)  as  the  primary
outcomes  to comprehensively  evaluate  the  effect  of  the  treatment.  QOL was  measured  by  the  Functional
Assessment  of  Cancer  Therapy-Lung  (FACT-L)  4.0  questionnaire.  Side  effects  and  safety  were  evaluated
at  the same  time.
Results: Of the  106  patients,  99  completed  the study.  After  treatment  and  follow-up  for PFS,  there  were
no  signiﬁcant  differences  in the  median  PFS  time  and  the  6-month  PFS  probability  between  the  two
groups.  However,  the 3-month  PFS  probability  in  the  trial group  was signiﬁcantly  higher  than  that  in the
control  group  (FAS,  PPS: P < 0.01).  For  QOL,  there  were signiﬁcant  differences  between  the two  groups  in
the following:  physical  well-being,  emotional  well-being,  functional  well-being,  lung  cancer  symptom
domain  and  total  score  of  the  FACT-L4.0  (FAS,  PPS:  P <  0.05).  There was  no  signiﬁcant  difference  in the
social  well-being  domain.  No  serious  adverse  side  effects  to  the  treatment  were  observed.
Conclusions:  CHM  is  well  tolerated  and  may  improve  the  QOL  of advanced  NSCLC  patients.  CHM  is worth
studying  in future  investigations.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. IntroductionLung cancer is the ﬁrst leading cause of cancer-related death
orldwide.1,2 It is estimated that more than one hundred million
eople die from lung cancer each year.3 Moreover, the morbidity
Abbreviations: CHM, Chinese herbal medicine; NSCLC, non-small-cell lung can-
er; BSC, best supporting care; PFS, progression-free survival; QOL, quality of life;
ACT-L, Functional Assessment of Cancer Therapy-Lung; FAS, full analysis set; PPS,
er-protocol analysis set.
∗ Corresponding author.
E-mail address: guowang yang@163.com (G. Yang).
ttp://dx.doi.org/10.1016/j.ctim.2015.12.008
965-2299/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
and mortality of lung cancer are increasing annually in China,4,5
indicating a major threat to health in this country. Non-small cell
lung cancer (NSCLC) accounts for over 80% of newly diagnosed lung
cancers.6 The only way  to cure patients with NSCLC is to completely
remove the tumor in a surgical procedure. As typical symptoms
are imperceptible during the early stages, approximately two-
thirds of patients are unresectable because of metastatic or locally
advanced disease at their initial diagnosis.7 If untreated, the median
survival time for NSCLC is only 4–5 months.8 Currently, the stan-
dard ﬁrst-line treatment for advanced NSCLC is platinum-based
combination regimen chemotherapy, which ranges in efﬁciency
from 20% to 40%,9 adding approximately 3 months to the median
progression-free survival (PFS) time10 and 8–10 months to the
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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edian overall survival (OS) time.11,12 In accordance with the
revious standard treatment modalities, ﬁrst-line chemotherapy
hould be administered for no more than six cycles in advanced
SCLC patients, and after documented disease control,9 patients are
ept waiting and under observation13 to restore their performance
tatus (PS) and immune system. If there is disease progression,
atients are recommended a second-line treatment. However, the
econd-line chemotherapy has lower efﬁciency, short-term remis-
ion, and quicker disease progression.14 In addition, approximately
0–80% of patients have no opportunity to receive second-line
hemotherapy.15
Maintenance therapy has emerged in recent years as a novel
herapeutic paradigm for advanced NSCLC that aims to sustain a
linically favorable state after ﬁrst-line chemotherapy. It refers to
ontinued use of the drug treatment until disease progression or
he occurrence of intolerable adverse events (AEs) if there is a sta-
le disease (SD) or better response after completion of the ﬁrst-line
hemotherapy. The theoretical foundation of the therapy originates
rom the Goldie–Coldman theory,16 which states that resistant and
lowly growing cancer cells remain after ﬁrst-line chemotherapy,
hich has primarily killed the sensitive and rapidly proliferating
ells. Use of different non-cross-resistant chemotherapy regimens
s effective in eradicating the remaining resistant cancer cells. In
ecent years, there are a number of clinical studies on mainte-
ance therapy, which has been shown to have a potential beneﬁt in
rolonging PFS.17–21 The National Comprehensive Cancer Network
NCCN) version 2.2013 recommends several cytotoxic agents and
arget agents for use in maintenance therapy.15 However, careful
onsideration of maintenance therapy is still required, and the fol-
owing should be noted: one of the major goals of maintenance
herapy is increasing the quality of life (QOL), but most studies
ave not evaluated the QOL; the selection of maintenance ther-
py depends on histologic type, PS, genetic alternations and other
actors, indicating that only some patients can beneﬁt from it; con-
inuing cytotoxic agents will result in cumulative toxicity, damage
mmune function, lower QOL and increase the risk of drug resis-
ance; and the prices of chemotherapy and targeted drugs are very
igh such that a proportion of patients cannot afford them, espe-
ially in a developing country. Therefore, the current maintenance
herapy in advanced NSCLC still excites debates and requires for
urther research, which presents opportunities for Chinese herbal
edicine (CHM) to treat the disease and act as maintenance therapy
t the same time.
CHM, which has a long history in China and has accumulated
ich experience in the treatment of malignant tumors, is widely
sed in the treatment of advanced NSCLC. Some studies have
hown that CHM combined with chemotherapy, radiotherapy and
argeted therapy can alleviate side effects of cancer treatment,
nhance short-term therapeutic effects, stabilize the disease and
mprove the long-term efﬁcacy of treatment.22–24 In regards to
atients who cannot accept conventional therapy, CHM can be
sed alone to ameliorate symptoms, improve QOL, and prolong
he survival time with a tumor.25 CHM shows an irreplaceable role
n the comprehensive treatment of advanced NSCLC.26 In fact, a
ajority of advanced NSCLC patients receive CHM as consolida-
ion therapy after completion of ﬁrst-line chemotherapy, which
ctually includes maintenance therapy. CHM has a deﬁnite advan-
age, including stabilizing tumor growth, relieving symptoms and
ild adverse events, which can help patients to “survive with a
umor”.27,28 It also meets a criterion that the optimal maintenance
herapy agent should be associated with an improvement in out-
ome, have good patient tolerance, and be devoid of cumulative
oxicities. Furthermore, CHM is not limited to treating patients
ith histologic type, PS, or genetic alternations and is subsequently
ery suitable for maintenance therapy. In China, some studies havees in Medicine 24 (2016) 81–89
reported that CHM serving as maintenance therapy can prolong PFS
and improve the QOL.29,30 However, studies about CHM as mainte-
nance therapy are limited, and almost all of the studies were small
sample, non-randomized controlled trials (RCT), which lack strong
evidence to prove that CHM can have an effective role as mainte-
nance therapy. According to our previous pilot study, 28 cases of
advanced NSCLC patients accepted CHM and best supported care
(BSC) as maintenance therapy; the median PFS was  5.0 months,
which showed a signiﬁcant beneﬁt compared with the literature
reporting placebo and BSC as maintenance therapy (median PFS
was 2.6 months).31 Therefore, a multicenter randomized controlled
study was carried out to evaluate the efﬁcacy and safety of using
CHM as maintenance therapy.
2. Patients and methods
2.1. Study design
This was  a multicenter, randomized, open-label, controlled trial.
The study was approved by the medical Ethics Committees of Bei-
jing Hospital of Traditional Chinese Medicine afﬁliated to Capital
Medical University, and written informed consent to participate
in the study was received by all of the participating patients. The
study was  conducted following the principles of the Declaration of
Helsinki, good clinical practices and local regulations.
2.2. Patients
2.2.1. Eligibility criteria included the following
No more than one week from completion of 4–6 cycles of
platinum-based ﬁrst-line induction therapy32 with radiographic
evidence of a complete response (CR) or partial response (PR) or
SD; a histologic or cytological diagnosis of stage IIIB or stage IV
NSCLC (using the seventh edition TNM staging system available at
the time the study was  conducted)33; between the ages of 18 and
75 years old; an estimated life expectancy of at least 3 months; an
Eastern Cooperative Oncology Group (ECOG) PS of 0–2; at least one
measurable lesion according to the Response Evaluation Criteria in
Solid Tumors (RECIST version 1.1)34; and adequate liver and kidney
function.
2.2.2. Exclusion criteria included the following
Known brain metastasis (except for stable metastases being
treated with stereotactic radiation or surgery); any serious con-
comitant systemic disorder, such as unstable angina pectoris,
myocardial infarction, signiﬁcant cardiac arrhythmia, stroke, or
severe hypertension; pregnancy or breast-feeding; mental disease;
allergies to any components of the study drug; unable to consent or
comply with the protocol; concurrent or planned chemotherapy or
targeted maintenance treatment or any other clinical and biochem-
ical test; and unwilling or unable to complete QOL questionnaires
and give written consent.
2.3. Treatment
Patients in the control group were treated with BSC rec-
ommended by the NCCN Cancer Palliative Care Guide (Version
1.2010)35 at any time during the study if it was felt to be in the
patient’s best interest. This included, but was not restricted to, anal-
gesics, paracentesis, psychosocial care, nutritional support, or blood
transfusions. Localized radiotherapy to alleviate pain was allowed,
provided that the radiation dose was  in the palliative range. How-
ever, no other anticancer therapies were permitted during the
study. Strict quality control measures for BSC were implemented
and monitored.
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Patients in the trial group were treated with BSC and CHM. CHM
reatment was applied with a decoction composed of 10–20 herb
arieties. The CHM was made based on a series process. First, based
n our extensive experience in clinical practice and in combination
ith previous studies36 and modern pharmacological studies, we
ummarized the characteristics of Chinese Medicine syndrome in
dvanced NSCLC. For each syndrome, we developed an appropriate
iagnostic criterion and corresponding ﬁxed prescription compo-
ition of 3–5 herbs (Appendix A). Then, based on the theory of
reatment according to syndrome differentiation combined with
ach patient’s symptoms, the Chinese Medicine expert determined
he syndromes and chose the corresponding prescriptions to form
he CHM treatment prescription (decoction). Due to the change
f syndrome over time, experts would re-determine syndromes
nd adjust the CHM treatment prescription every two weeks. The
HM was given orally, 200 ml  each time, twice daily. The treatment
egan the day of random assignment and continued until disease
rogression, patient-physician decision, or unacceptable toxicity.
atient follow-ups were done by regular monthly telephone calls
r during their monthly visit to the hospital until progression was
bserved.
.4. Outcomes
.4.1. PFS
PFS was deﬁned as the time from the date of randomization to
he time of disease progression or death. It was based on the day as a
nit. Tumor assessments were performed by the radiologist blinded
o group allocation at each investigative site, per RECIST (version
.1) requirements,34 at baseline and every two month during the
tudy period until documented disease progression, death or study
losure. We  compared Median PFS time and the PFS probabilities
f 3 months and 6 months between the two groups.
.4.2. QOL
The Functional Assessment of Cancer Treatment-Lung (FACT-
) Chinese version 4.0 questionnaire was adopted. It has been
onﬁrmed that the instrument has good reliability, validity and
esponsiveness and can be used to measure QOL for Chinese
atients with lung cancer.37 There are 36 questions loaded on 5
omains of FACT-L, which include physical well-being (7 ques-
ions), social well-being (7 questions), emotional well-being (6
uestions), functional well-being (7 questions) and the lung can-
er symptom (9 questions) domain. The questionnaire was in the
ypical format of a 5-point Likert scale, in which each question
anged from 0 to 4, positive questions scored forward, and neg-
tive questions scored in reverse. The domain score was  calculated
y summing each question’s score. The total score was  the sum of
ach domain score. For each domain and the total score, the higher
he score was, the better the QOL of the patients. The date of QOL
as observed and recorded at baseline (week 0) and at the 4th week
week 4) and the 8th week (week 8) during the treatment period.
.4.3. Safety
Routine urine was collected and liver and kidney function and
lectrocardiograms (ECG) were assessed before and after treat-
ent, as were AEs recorded during treatment. The AEs were graded
ccording to the Common Terminology Criteria for Adverse Events
CTCAE), version 3.0.38
.4.4. Calculation of sample size
The primary end point of this study was PFS. To determineample size, the following ﬁxed design parameters were used39: a
wo-sided 0.05 signiﬁcance level, 90% power, randomization ratio
f 1:1, and all patients enrolled had an expected time of no more
han 26 months and a total accrual duration of no more than 33es in Medicine 24 (2016) 81–89 83
months. Interim analysis was not planned. Considering that there
was no previous RCT in this setting, to our knowledge, median PFS
in the BSC arm was assumed to be 2.6 months based on our retro-
spective study and a literature review.40 Our previous single-arm
plot trial showed that the median PFS in CHM/BSC was  5 months.
Thus, 106 patients in both arms were expected, with 53 patients in
each group.
2.4.5. Randomization
Patients were chronologically randomized into two groups, and
the distribution ratio was  1:1. A random number from 001 to 106
was generated by SPSS 19.0 and saved in a sealed envelope. Treat-
ment allocation occurred when the participant met  the inclusion
criteria and signed the informed consent. The result of random-
ization was opened to patients and investigators along with the
performance of the study. To strengthen the quality control for
this open-label trial, an investigator separate from all of the clinical
researchers was  assigned in each center as the contact person who
preserved and recorded the randomization information.
2.4.6. Statistical analysis
All clinical data were analysed using SPSS 19.0 by an indepen-
dent clinical statistician uninvolved in providing the intervention
or management. The outcomes were analysed by the intention-to-
treat (ITT) model and supplemented by per-protocol (PP) analysis.
Student’s t-test or the Chi-square test was used to compare the two
groups’ baseline characteristics. PFS assessments for patients with-
out disease progression at the end of the study were considered as
censored data. For each treatment arm, the Kaplan–Meier method
was used to estimate PFS curves and calculate the median PFS and
associated 95% Conﬁdence Interval (CI) and survival probabilities
of 3 months and 6 months. The PFS curves were compared using
the log rank test. For the QOL assessment, the independent-sample
t-test or the Mann–Whitney U-test, based on the distribution, was
used to compare differences between the two  groups at speciﬁc
time points (baseline, 4 week treatment and 8 week treatment).
Repeated measures were used to compare differences over time
for continuous observation. All P values were two-tailed, and an 
level less than 0.05 was considered statistically signiﬁcance.
3. Results
3.1. Patient enrollment and comparison of general information
All patients were recruited (September 2011–March 2014) from
4 hospitals. Seven patients did not fully complete the study due to
violations of the protocol during the study. At the end, 99 patients
completed the study treatment. No patient was lost to follow-up.
Therefore, the per-protocol analysis set (PPS) population was 99,
and the full analysis set (FAS) population was 106. Patient enroll-
ment and completion values for the study are shown in Fig. 1.
There was no signiﬁcant difference in age, gender, staging,
pathological type, chemotherapy cycle, response after standard
chemotherapy, or ECOG performance status between the two
groups (FAS, PPS: P > 0.05). The comparison of general information
at baseline between the two  groups is shown in Table 1.
3.2. Comparison of PFS
The cut-off date for analysis was  July 2014, resulting in a median
follow-up time at day 146 (censoring those who were progres-
sion free at the end of the study); at the cut-off date, 95 patients
had disease progression (89.6%). The number of patients who were
progression free in the trial group and control group were 7 and
4, respectively. There was  no signiﬁcant difference in the aspects
of the median PFS time and the 6-month PFS probability between
84 Y. Han et al. / Complementary Therapies in Medicine 24 (2016) 81–89
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he two groups. However, the 3-month PFS probability in the trial
roup was signiﬁcantly higher than that in the control group (FAS,
PS: P < 0.01). The median PFS time, 3-month PFS probability and
-month PFS probability of both groups are shown in Table 2. The
FS curves in a per-protocol and full analysis population are shown
n Fig. 2A and B, respectively..3. Comparison of QOL
Before treatment, there was no signiﬁcant difference in each
omain score and its total score between the two groups (P > 0.05).
able 1
omparison of general information between the two groups.
Variable Per-protocol analysis set 
CHM + BSC group(n = 52) BSC group(n = 47) P
Mean age, year ±SD 59.19 ± 9.44 59.63 ± 10.06 0
Range  27–75 31–75 
Sex  0
Male  33 24 
Female 19 23 
Stagingb 0
IIIB  9 5 
IV  43 42 
Pathological type 0
Adenocarcinoma 35 29 
Squamous carcinoma 13 12 
Other type 4 6 
Chemotherapy cycle 0
4  24 16 
5  7 6 
6  21 25 
Responsec 0
CR+PR  9 11 
SD  43 36 
ECOG PS 0
0  6 10 
1  26 19 
2  20 18 
otes: CHM—Chinese herbal medicine; BSC—best support care; n—number of patients 
S—performance status; ECOG—Eastern Cooperative Oncology Group.
a T-test or Chi-square test.
b Based on TNM Classiﬁcation, 7th edition.
c Response after standard ﬁrst-line chemotherapy determined by RECIST criteria.nd completion of the study.
The QOL scores of the trial group continued to increase over time
and were signiﬁcantly higher than those of the control group
for physical well-being (Fig. 3A, P ≤ 0 .04), functional well-being
(Fig. 3B, P ≤ 0.012), lung cancer symptom (Fig. 3C, P ≤ 0.020) and
total score (Fig. 3D, P ≤ 0.026). There was also an increase over time
in the score for the emotional well-being domain in the trial group
but a decrease in the control group, and the difference between
the two groups was signiﬁcant (Fig. 3E, P ≤ 0.025). However, the
score for the social well-being domain barely changed over time
and showed no difference between the groups (Fig. 3F, P ≥ 0.628). At
the 4th and 8th weeks, the trial group had higher QOL scores com-
Full analysis set
a CHM + BSC group(n = 53) BSC group(n = 53) Pa
.826 59.42 ± 9.49 59.46 ± 9.93 0.981
27–75 31–75
.213 0.323
34 29
19 24
.342 0.403
9 6
44 47
.687 0.796
36 34
13 13
4 6
.411 0.201
24 16
7 6
22 31
.451 0.632
10 12
43 41
.378 0.325
6 11
27 21
20 21
in each group; CR—complete response; PR—partial response; SD—stable disease;
Y. Han et al. / Complementary Therapies in Medicine 24 (2016) 81–89 85
Table  2
Median PFS time and 3-month/6-month PFS rates of the two  groups.
Full analysis set Per-protocol analysis set
CHM + BSC group N = 53 BSC group N = 53 HR (95%CI) P CHM + BSC group N = 52 BSC group N = 47 HR (95%CI) P
Median PFS time 165 119 0.791 0.260 163 140 0.848 0.440
(95%CI), day (137–192) (79–158) (0.527–1.189) (136–190) (100–180) (0.556–1.294)
3-Month PFS 0.005 0.005
Rate/%  84.9 67.9 84.6 68.1
6-Month PFS 0.141 0.377
Rate/%  40.6 31.2 39.3 33.1
Notes: CHM—Chinese herbal medicine; BSC—best support care; PFS—progression free survival; HR—hazard risk; CI—conﬁdence interval.
Fig. 2. Unadjusted, unstratiﬁed PFS for the maintenance therapy (from randomization) for the per-protocol survival population (A) and the full analysis population (B).
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Fig. 3. Change in quality of life and comparison of FACT-L4.0 questionnaire in physical well-being, social well-being, emotional well-being, functional well-being, the lung
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aancer  symptom domain and total score at baseline and at the 4th and 8th weeks b
ared with the control group for physical well-being (P ≤ 0.022),
motional well-being (P ≤ 0 .013), functional well-being (P ≤ 0.005),
ung cancer symptoms (P ≤ 0.037), and total scores (P ≤ 0.015).
.4. Evaluation of safety
There were no signiﬁcant differences in routine blood, urine
nd stool tests, liver and kidney function tests and ECG before
nd after treatment in each group. AEs were recorded when they
ccurred. However, there was no signiﬁcant difference between
he two groups in terms of AEs (P > 0.05). Ten cases in the trial
roup experienced dry mouth, nausea, loss of appetite, and diar-
hea, which appeared after taking CHM and may  be associated with
HM treatment. Five cases in the control group experienced dry
onth, nausea, constipation, and loss of appetite, which may  be
aused by the BSC treatment. The grade of these AEs was  1, and
fter temporary CHM withdrawal or symptomatic treatment, thesen the two  groups.
symptoms disappeared in a week. No patients quit the trial because
of the AEs.
4. Discussions
In recent years, maintenance therapy of advanced NSCLC has
become a hot spot for research. The U.S. National Cancer Institute’s
medical dictionary deﬁnes maintenance therapy as “any treatment
that is given to help keep cancer from progressing after it has been
successfully controlled by the appropriate initial front-line therapy;
it may  include treatment with drugs, vaccines, or antibodies, and it
should be given for a long time”.13 CHM is based on a unique theory
formed from long-term practical experience. For the last thousand
years, CHM has been widely practiced in China and has recently
been widely used internationally as a complementary and alter-
native therapy. More than 90% of modern Chinese cancer patients
have received CHM treatment.41 Recently, CHM has also been used
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broad and is well accepted in many countries, particularly for
he treatment of oncology.42 Nevertheless, more rigorous trials are
equired to further verify CHM efﬁcacy. Therefore, we conducted
he study to evaluate CHM as maintenance therapy considering
dvanced NSCLC patients’ tumor control and QOL.
Our results showed that PFS was not signiﬁcantly different in
he two groups, despite an extended period of PFS time in the trial
roup. Furthermore, the 3-month rate of disease progression was
igniﬁcantly reduced in the trial group, but the 6-month PFS prob-
bilities of the two groups were similar, which reﬂected that the
HM may  have a short-term beneﬁt for maintenance therapy of
dvanced NSCLC. However, it appeared that the advantages of CHM
ere not sustained, which may  be related to the rapid deterioration
ver time of advanced NSCLC. In addition, it should be noted that
he study did not chose overall survive (OS) as an endpoint to eval-
ate survival. The purpose of our study was to explore if CHM could
ave an effective role as maintenance therapy, and it is not possi-
le to control for post-study events in the clinical trial that would
llow for fair assessment of a new therapy. Given this real world
hallenge, the PFS endpoint becomes even more important, not just
or trials evaluating maintenance treatment strategies but also for
ll future deﬁnitive therapeutic trials in this patient population.
QOL is an important prognostic factor43 and a signiﬁcant pre-
ictor of survival44 in advanced NSCLC. The change of the medical
odel from the bio-medical model to a bio-psycho-social medical
odel makes us pay more attention to QOL and not just focus on
ime of survival in the treatment of advanced cancer patients. The
ncologic Drugs Advisory Committee (U.S. Food and Drug Admin-
stration) has also recommended that the QOL should be observed
s an important endpoint in cancer clinical trials.45 Silvestri G46
eported that a majority of patients were more willing to choose
 method of treatment that can alleviate symptoms, although this
tudy could not bring about prolonged survival. Because advanced
ung cancer patients are usually accompanied by a persistent cough,
hest tightness, wheezing, pain and other symptoms that can result
n a limitation of daily activities, they cannot take care of them-
elves and must rely on family members. In addition, because of
he difﬁculty of cancer therapy, rapid progression of disease, and
nancial burden, patients experience low self-esteem, depression,
nxiety and other damages to their mental well-being. There-
ore, for advanced NSCLC, it is important to treat these patients to
mprove their QOL. However, there is a lack of data about QOL with
aintenance therapy. We  chose QOL as one of the main end points
f our study to build knowledge in this area. Because QOL is sub-
ective, a questionnaire is an important tool for its assessment. Our
tudy adopted the FACT-L questionnaire, which was developed by
he Chicago Rush-Presbyterian-St. Luke’s Medical Center for can-
er research and is widely used in the world. Our result showed
hat after treatment, the improvement of the physical well-being
omain (16.7% vs 3.48%), functional well-being domain (12.23%
s 2.93%), emotional well-being domain (11.36% vs 4.53%), lung
ancer symptoms well-being domain (13.28% vs 9.41%), and total
core (11.11% vs 2.59%) in the trial group were better than those
n the control group. However, the social well-being domain was
ot improved. The items of this domain are all focused on sociales in Medicine 24 (2016) 81–89 87
support and emotional intimacy between family and friends. Thus,
we think the score of this domain may  mainly depend on family,
friends, neighbors or others to provide various forms of support and
help.
However, there are some limitations to this study. First, this
study was performed as an open-label study, but some measures
were taken to strengthen quality control. The development of the
CHM treatment followed strict procedures aiming to conﬁrm the
syndrome diagnostic criteria and treatment standards to avoid
subjective arbitrary treatment. Moreover, CHM took into account
the requirements of individual care combined with standard ther-
apy. It was  possible to form CHM standards in treating advanced
NSCLC, which is worth applying in clinics and beneﬁcial to dis-
covering effective compounds and monomers. To ensure accurate
PFS measurement, a strict schedule of efﬁcacy assessment and
patient follow-up was implemented, and a radiological evaluation
or diagnosis was performed every 2 months; to further increase
the conﬁdence in PFS assessment, an independent review of radio-
graphic images was frequently performed. For QOL, all patients
were required to complete the questionnaire by themselves and
the researchers could not give the suggestion, so we are conﬁ-
dent about the accuracy of our PFS and QOL data. In addition,
the randomization, allocation, and data management were han-
dled by independent individuals. Second, a placebo for CHM was
not adopted in the study; the reason for this is that a placebo of a
CHM decoction is difﬁcult to make, and it is difﬁcult to obtain ethi-
cal patient consent. Third, due to the stringent inclusion criteria of
patients, it became hard to collect qualiﬁed patients, and we spent
almost three years working to complete the study.
5. Conclusions
Overall, our ﬁndings suggest a limited role for CHM as main-
tenance therapy to prolong patients’ PFS time, but it may  be
beneﬁcial in improving the QOL. The U.S. Food and Drug Adminis-
tration has recommended that the beneﬁcial effects on QOL  and/or
survival be the basis for approval of new anticancer drugs. There-
fore, from a regulatory standpoint, drugs that have an impact on
survival or demonstrate a favorable effect on QOL are more impor-
tant than most other traditional measures used to assess efﬁcacy,
such as objective tumor response.45 Thus, CHM may  be considered
as maintenance treatment, and further research is required and
worthwhile.
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ppendix A. Syndrome types, syndrome diagnostic criteria
nd corresponding prescription in advanced NSCLC
Syndrome types Syndrome diagnostic criteria 
Main symptoms Se
Lung Dyspnoea, shortness of breath, low
cough sound, easier to catch cold
Sp
w
toQi  deﬁciency
Spleen Anorexia, poor appetite, abdominal
distention after eating, fatigue, loose stool
A
o
pQi  deﬁciency
Kidney Soreness and weakness of waist and knees,
frequent micturition, dribble of urine, frequent
urination at night, incontinence of urine
Sp
d
em
p
pQi  deﬁciency
Kidney Soreness and weakness of waist and
knees, loss of hair, fear of cold
Fr
lo
fu
thYang  deﬁciency
Spleen Loose stool, diarrhea with undigested
food
T
ed
pYang  deﬁciency
Lung Dry and withered lips, dry throat, dry
cough
T
ch
reYin  deﬁciency
Kidney Soreness of loins, tinnitus, dysphoria
with feverish sensation in chest, palms
and soles
E
d
to
thYin  deﬁciency
Blood Pale complexion and lips, dizziness,
palpitation
Sp
n
toDeﬁciency
Blood Stabbing and ﬁxed pain increasing
with pressure, dark purple tongue or
spotted, hesitant pulse
D
d
Stasis
Phlegm Cough, coughing of phlegm, oppression
in  chest, suffocation
A
p
to
se
oCoagulation
Qi Cough with shortness of breath,
oppression in chest, suffocation,
distending pain in abdomen
D
ﬂ
p
fuStagnation
Heat-toxicity Fever, red complexion, much yellow phlegm,
cough with bad breath
Fe
u
ra
Toxin  retention Rapid tumor progression, increasing radicular symptom
was seriously damaged, increase of tumor markers
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